Interventions of Interest:

  • lecanemab (Leqembi, Eisai Co., Ltd)

The independent appraisal committee voted that currently available evidence is not adequate to demonstrate a net health benefit for lecanemab when compared to supportive care. Using best estimates from current data, ICER analyses suggest lecanemab would achieve common thresholds for cost-effectiveness if priced between $8,900 – $21,500 per year.

Final Documents

Final Report and Meeting SummaryDownload
Final Policy RecommendationsDownload
Report-at-a-GlanceDownload
Draft Evidence ReportDownload
Responses to Public CommentsDownload

ICER’s Chief Medical Officer David Rind, MD stated:

“Individuals and families dread Alzheimer’s disease, and the first therapy that effectively halts or reverses dementia will warrant a very high price in the US health system. Current evidence strongly suggests that lecanemab mildly slows the loss of cognition in patients with early Alzheimer’s disease. However, given the risks of brain swelling and bleeding, particularly when lecanemab is used outside of clinical trials, our report concluded that significant uncertainties remain as to whether the average benefits of lecanemab will exceed its risks.

A majority of the California Technology Assessment Forum was clearly unconvinced that the current evidence adequately demonstrates that lecanemab provides a net benefit to patients. In addition, using the best current data from the clinical trials, at its announced list price lecanemab exceeds typical thresholds for cost-effectiveness and, given the large number of patients with Alzheimer’s disease, it is particularly important that therapies for Alzheimer’s disease be priced in line with their value to patients.”

For questions or to request a Spanish translated Report-at-a-Glance for this assessment, please contact Kelsey Gosselin, Program Manager, at kgosselin@icer.org.

View the Key Stakeholder List.